Psychiatr Prax 2004; 31: 233-237
DOI: 10.1055/s-2004-828475
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Gewichtszunahme während der Behandlung mit Antipsychotika: Klinische Relevanz, Pathophysiologie und therapeutische Möglichkeiten

Weight Gain During Treatment with Antipsychotics: Clinical Relevance, Pathophysiology, and Therapeutical StrategiesHubertus  Himmerich1 , Andreas  Schuld2 , Thomas  Pollmächer1, 2
  • 1Max-Planck-Institut für Psychiatrie, München
  • 2Zentrum für psychische Gesundheit, Klinikum Ingolstadt
Further Information

Publication History

Publication Date:
08 December 2004 (online)

Zusammenfassung

Patienten, die unter antipsychotischer Therapie an Körpergewicht zunehmen, haben ein erhöhtes Risiko für die Entwicklung der Adipositas und der mit ihr assoziierten Krankheiten. Pathophysiologisch tragen zu diesen Gewichtsveränderungen die psychiatrische Grunderkrankung selbst, Veränderungen in den Neurotransmittersystemen und in den Zytokin- und Hormonsystemen bei. Die Therapie der antipsychotikainduzierten Gewichtszunahme umfasst diätetische, verhaltenstherapeutische und pharmakologische Maßnahmen. Mögliche, aber noch nicht in größeren Studien geprüfte pharmakotherapeutische Add-on-Strategien könnten Behandlungsversuche mit Ephedrin, Sibutramin, Orlistat, Topiramat, Nizatidin, Naltrexon, Metformin, Amantadin oder Reboxetin darstellen.

Abstract

The clinical relevance of drug-induced weight changes is due to the development of obesity, increased rates of morbidity and reduced treatment compliance, even if the psychopharmacological treatment is effective. Possible underlying causes of weight gain in patients treated with antipsychotic drugs are the psychiatric disorder itself, and changes in the neurotransmitter, cytokine and hormone systems. Clinical management of psychopharmacologically induced weight gain includes diet, behavioral and pharmacological therapy. Possible add-on strategies - based on case reports and small studies - are ephedrine, sibutramine, orlistat, topiramate, nizatidine, naltrexone, metformin, amantadine, and reboxetine.

Literatur

  • 1 Himmerich H, Schuld A, Pollmächer T. Gewichtszunahme unter Psychopharmakotherapie und ihre klinische Bedeutung. Dt Ärztebl 2004, im Druck
  • 2 Pijl H, Meinders A E. Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.  Drug Saf. 1996;  14 329-342
  • 3 Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C, Weiden P J. Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156 1686-1696
  • 4 Marder S R, McQuade R D, Stock E, Kaplita S, Marcus R, Safferman A Z, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.  Schizophr Res. 2003;  61 123-136
  • 5 Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics.  Br J Psychiatry. 1988;  153 214-217
  • 6 Allison D B, Casey D E. Antipsychotic-induced weight gain: a review of the literature.  J Clin Psychiatry. 2001;  62 22-31
  • 7 Stedman T, Welham J. The distribution of adipose tissue in female in-patients receiving psychotropic drugs.  Br J Psychiatry. 1993;  162 249-250
  • 8 Aronne L J. Epidemiology, morbidity, and treatment of overweight and obesity.  J Clin Psychiatry. 2001;  62 13-22
  • 9 Kraepelin E. Lectures on Clinical Psychiatry. New York; William Wood & Company 1904
  • 10 Kryspin-Exner W. Beiträge zum Verlauf des Körpergewichtes bei Psychosen.  Wiener Klinische Wochenschrift. 1947;  59 531-534
  • 11 Klett C J, Caffey E M. Weight changes during treatment with phenothiazine derivates.  J Neuropsychiatry. 1960;  2 102-108
  • 12 Singh M M, Dios L V De, Kline N S. Weight as a correlate to clinical response to psychotropic drugs.  Psychosomatics. 1970;  11 562-570
  • 13 Czobor P, Volavka J, Sheitman B, Lindenmayer J P, Citrome L, McEvoy J, Cooper T B, Chakos M, Lieberman J A. Antipsychotic-induced weight gain and therapeutic response: a differential association.  J Clin Psychopharmacol. 2002;  22 244-251
  • 14 Gordon H L, Groth C. Weight change during and after hospital treatment.  Arch Gen Psychiatry. 1964;  10 115-119
  • 15 Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker W W. Weight gain induced by clozapine.  Eur Neuropsychopharmacol. 1995;  5 437-440
  • 16 Himmerich H, Schuld A, Haack M, Kaufmann C, Pollmächer T. Early prediction of changes in weight during six weeks of treatment with antidepressants. J Psychiatr Res 2004, im Druck
  • 17 Stunkard A J, Fernstrom M H, Price A, Frank E, Kupfer D J. Direction of weight change in recurrent depression.  Arch Gen Psychiatry. 1990;  47 857-860
  • 18 Baptista T, Teneud L, Contreras Q, Alastre T, Burguera J L, Burguera M de, Baptista E de, Weiss S, Hernandez L. Lithium and body weight gain.  Pharmacopsychiatry. 1995;  28 35-44
  • 19 Paykel E S, Mueller P S, Del V. Amitriptyline, weight gain and carbohydrate craving: a side effect.  Br J Psychiatry. 1973;  123 501-507
  • 20 Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.  J Psychiatr Res. 2003;  37 193-220
  • 21 Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine.  J Clin Exp Psychopathol. 1959;  20 53-57
  • 22 Shen W W. A history of antipsychotic drug development.  Compr Psychiatry. 1999;  40 407-414
  • 23 Schwartz M W, Woods S C, Porte D J, Seeley R J, Baskin D G. Central nervous system control of food intake.  Nature. 2000;  404 661-671
  • 24 Kraus T, Haack M, Schuld A, Hinze-Selch D, Kühn M, Uhr M, Pollmächer T. Body weight and leptin plasma levels during treatment with antipsychotic drugs.  Am J Psychiatry. 1999;  156 312-314
  • 25 Hegyi K, Fulop K A, Kovacs K J, Falus A, Toth S. High leptin level is accompanied with decreased long leptin receptor transcript in histamine deficient transgenic mice.  Immunol Lett. 2004;  92 193-197
  • 26 Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice.  Diabetes. 2001;  50 385-391
  • 27 Hauner H, Bender M, Haastert B, Hube F. Plasma concentrations of soluble TNF-alpha receptors in obese subjects.  Int J Obes Relat Metab Disord. 1998;  22 1239-1243
  • 28 Borst S E. The role of TNF-alpha in insulin resistance.  Endocrine. 2004;  23 177-182
  • 29 Kern P A, Saghizadeh M, Ong J M, Bosch R J, Deem R, Simsolo R B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase.  J Clin Invest. 1995;  95 2111-2119
  • 30 Schuld A, Kraus T, Haack M, Hinze-Selch D, Kuhn M, Pollmächer T. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine.  Schizophr Res. 2000;  43 164-166
  • 31 Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmächer T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight.  Psychopharmacology. 2000;  149 163-169
  • 32 Pollmächer T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels.  J Clin Psychopharmacol. 1996;  16 403-409
  • 33 Pollmächer T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol.  Am J Psychiatry. 1997;  154 1763-1765
  • 34 Kraus T, Zimmermann U, Schuld A, Haack M, Hinze-Selch D, Pollmächer T. Zur Pathophysiologie der Gewichtsregulation im Rahmen der Therapie mit Psychopharmaka.  Fortschr Neurol Psychiatr. 2001;  69 116-137
  • 35 Astrup A, Toubro S, Cannon S, Hein P, Madsen J. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study.  Metabolism. 1991;  40 323-329
  • 36 McNeely W, Goa K L. Sibutramine. A review of its contribution to the management of obesity.  Drugs. 1998;  56 1093-1124
  • 37 Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-lowcalorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.  Am J Med. 1999;  106 179-184
  • 38 Davidson M H, Hauptman J, DiGirolamo M, Foreyt J P, Halsted C H, Heber D. et al . Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.  JAMA. 1999;  281 235-242
  • 39 Finer N, James W P, Kopelman P G, Lean M E, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.  Int J Obes Relat Metabol Dis. 2000;  24 306-313
  • 40 Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar H P, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.  Lancet. 1998;  352 167-172
  • 41 Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain.  J Clin Psychopharmacol. 2000;  20 716-717
  • 42 Dursun S M, Devarajan S. Clozapine weight gain, plus topiramate weight loss.  Can J Psychiatry. 2000;  45 198
  • 43 Stoa-Birketvedt G, Paus P N, Ganss R, Ingebretsen O C, Florholmen J. Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes.  Int J Obes Relat Metabol Dis. 1998;  22 1041-1045
  • 44 Stoa-Birketvedt G. Effect of cimetidine suspension on appetite and weight in overweight subjects.  BMJ. 1993;  306 1091-1093
  • 45 Sacchetti E, Guarneri L, Bravi D. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.  Biol Psychiatry. 2000;  48 167-168
  • 46 Yim G K, Lowy M T. Opioids, feeding, and anorexias.  Fed Proc. 1984;  43 2893-2897
  • 47 Bertino M, Beauchamp G K, Engelman K. Naltrexone, an opioid blocker, alters taste perception and nutrient intake in humans.  Am J Physiol. 1991;  261 R59-R63
  • 48 Levine A S, Billington C J. Opioids. Are they regulators of feeding?.  Ann N Y Acad Sci. 1989;  575 209-219
  • 49 Zimmermann U, Rechlin T, Plaskacewicz G J, Barocka A, Wildt L, Kaschka W P. Effect of naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study.  Biol Psychiatry. 1997;  41 747-749
  • 50 Morrison J A, Cottingham E M, Barton B A. Metformin for weight loss in pediatric patients taking psychotropic drugs.  Am J Psychiatry. 2002;  159 655-657
  • 51 Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment.  Eur Neuropsychopharmacol. 2001;  11 181-182
  • 52 Correa N, Opler L A, Kay S R, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics.  J Clin Psychopharmacol. 1987;  7 91-95
  • 53 Kamath V, Jones C N, Yip J C, Varasteh B B, Cincotta A H, Reaven G M, Chen Y D. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women.  Diabetes Care. 1997;  20 1697-1701
  • 54 Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster J L, Cincotta A H, DeFronzo R A. Bromocriptine: a novel approach to the treatment of type 2 diabetes.  Diabetes Care. 2000;  23 1154-1161
  • 55 Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.  Am J Psychiatry. 2003;  160 297-302
  • 56 Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L. Drug induced weight gain, an impediment to successful pharmacotherapy: Focus on antipsychotics.  Curr Drug Targets. 2004;  5 279-299

Prof. Dr. med. Thomas Pollmächer

Zentrum für psychische Gesundheit · Klinikum Ingolstadt

Krumenauerstraße 25

85049 Ingolstadt

Email: thomas.pollmaecher@klinikum-ingolstadt.de